Back to trial details

Intake questionnaire

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Applying to Vanderbilt University Medical Center · Nashville, Tennessee

Answer a few short questions to share with the research team.

0 of 3 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with HR+/HER2-negative Breast Cancer?
3. Are you able to travel to Nashville for study visits?